Against all odds: anti-IgE for intrinsic asthma?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23709757.
- Also identified by DOI 10.1136/thoraxjnl-2013-203738 and PMC identifier 3888607.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.
Medical subject headings
- Anti-Asthmatic Agents
- Antibodies, Anti-Idiotypic
- Antibodies, Monoclonal, Humanized
- Asthma